(Based on Intent to Use) Financing and funding services; providing funding for investigators, inventors, universities, research institutes and other academic entities; funding of research and product development; information, advisory and consultancy services in relation to all of the aforesaid services

Providing online non-downloadable electronic publications in the nature of newsletters, journals, and books in the field of cannabinoid-based medicines; arranging, conducting and organisation of educational conferences, congresses, seminars and symposiums in the field of cannabinoid-based medicines; information, advisory and consultancy services in relation to all of the aforesaid services

Scientific and technological services and research and design relating thereto, namely, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services